Cargando…
Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
PAGEPress Publications, Pavia, Italy
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477309/ https://www.ncbi.nlm.nih.gov/pubmed/34667489 http://dx.doi.org/10.4081/oncol.2021.564 |
| _version_ | 1784575816053555200 |
|---|---|
| author | Negri, Francesca Porta, Camillo |
| author_facet | Negri, Francesca Porta, Camillo |
| author_sort | Negri, Francesca |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8477309 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | PAGEPress Publications, Pavia, Italy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84773092021-10-18 Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? Negri, Francesca Porta, Camillo Oncol Rev Editorial PAGEPress Publications, Pavia, Italy 2021-09-22 /pmc/articles/PMC8477309/ /pubmed/34667489 http://dx.doi.org/10.4081/oncol.2021.564 Text en ©Copyright: the Author(s) https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Editorial Negri, Francesca Porta, Camillo Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? |
| title | Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? |
| title_full | Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? |
| title_fullStr | Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? |
| title_full_unstemmed | Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? |
| title_short | Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? |
| title_sort | donafenib in chinese patients with advanced hepatocellular carcinoma (hcc): really a new standard of care, or should we change paradigm for drug development in hcc? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477309/ https://www.ncbi.nlm.nih.gov/pubmed/34667489 http://dx.doi.org/10.4081/oncol.2021.564 |
| work_keys_str_mv | AT negrifrancesca donafenibinchinesepatientswithadvancedhepatocellularcarcinomahccreallyanewstandardofcareorshouldwechangeparadigmfordrugdevelopmentinhcc AT portacamillo donafenibinchinesepatientswithadvancedhepatocellularcarcinomahccreallyanewstandardofcareorshouldwechangeparadigmfordrugdevelopmentinhcc |